Holen Sie sich die Stockscreener-App
8.98
11.55%
0.93
Handel nachbörslich:
9.58
0.60
+6.68%
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
CervoMed (CRVO) Retains Buy Rating Amidst Steady Price Target | CRVO Stock News - GuruFocus
CervoMed to report 32-week extension phase results for DLB treatment - Investing.com Australia
CervoMed to Present New Data from Phase 2b RewinD-LB Study - GlobeNewswire
CervoMed to Reveal Critical 32-Week RewinD-LB Trial Results for Lewy Body Dementia Treatment at AAIC 2025 - Stock Titan
What analysts say about CervoMed Inc. stockMarket-leading growth rates - jammulinksnews.com
CervoMed Inc. Stock Analysis and ForecastAccelerated financial growth - Autocar Professional
Is CervoMed Inc. a good long term investmentDouble or triple returns - Autocar Professional
What drives CervoMed Inc. stock priceExtraordinary performance - jammulinksnews.com
CervoMed’s Dementia Drug Saga Tests Investor Patience And Nerves - Finimize
How CervoMed Inc. stock performs during market volatilityStrategic High Profit Opportunities - Newser
Why CervoMed Inc. stock attracts strong analyst attentionTrend Based Entry Alerts - Newser
What makes CervoMed Inc. stock price move sharplyFree Stock Selection with 300% Return - Newser
Brokerages Set CervoMed Inc. (NASDAQ:CRVO) Price Target at $22.57 - Defense World
CervoMed Strengthens Leadership with Technical Operations Hire to Advance Neflamapimod Toward Phase 3 - MSN
CervoMed Inc. to Present Late-Breaking Data on Neflamapimod at Alzheimer’s Association International Congress 2025 - Nasdaq
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025 - GlobeNewswire
Late-Breaking Phase 2b Results: CervoMed's Novel DLB Drug Shows Effects on Clinical Progression - Stock Titan
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 2000 Dynamic Index - MarketScreener
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 3000E Index - MarketScreener
CervoMed Inc.(NasdaqCM: CRVO) dropped from Russell 2000 Index - MarketScreener
CervoMed Inc. (NASDAQ:CRVO) Shares Bought by Rhumbline Advisers - Defense World
CervoMed Stockholders Approve Key Proposals at Annual Meeting - TipRanks
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
CervoMed’s (CRVO) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Pric - GuruFocus
CervoMed (CRVO) Receives Continued 'Buy' Rating with Target Price Held Steady | CRVO Stock News - GuruFocus
CervoMed (CRVO) Strengthens Leadership with Key Executive Appoin - GuruFocus
CervoMed (CRVO) Strengthens Leadership with Key Executive Appointment | CRVO Stock News - GuruFocus
CervoMed appoints Marco Verwijs as EVP, technical operations - TipRanks
CervoMed Announces New Hire to Support Neflamapimod Development and Commercialization - GlobeNewswire
CervoMed Accelerates Phase 3 DLB Drug Development With Key Manufacturing Expert Hire - Stock Titan
CRVOCervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates - mx.advfn.com
Nuveen Asset Management LLC Acquires 22,104 Shares of CervoMed Inc. (NASDAQ:CRVO) - Defense World
BNP Paribas Financial Markets Purchases New Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):